SML3017
甲磺酸乐伐替尼
≥98% (HPLC)
别名:
4-[3-氯-4-(N’-环丙基脲)苯氧基]-7-甲氧喹啉-6-甲酰胺甲磺酸盐, 4-[3-氯-4-[(环丙基羰基)氨基]苯氧基]-7-甲氧基-6-喹啉甲酰胺甲磺酸盐, 4-[3-氯-4-[[(环丙胺)羰基]氨基]苯氧基]-7-甲氧基-6-喹啉甲酰胺甲基磺酸盐(1:1), E 7080甲磺酸盐, E-7080甲磺酸盐, E7080甲磺酸盐, ER-203492-00甲磺酸盐, 乐伐替尼甲基磺酸盐
登录查看公司和协议定价
所有图片(1)
About This Item
经验公式（希尔记法）:
C21H19ClN4O4 · CH4O3S
CAS号:
分子量:
522.96
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
powder
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
2-8°C
SMILES 字串
O=C(C1=CC2=C(OC3=CC=C(C(Cl)=C3)NC(NC4CC4)=O)C=CN=C2C=C1OC)N.O=S(O)(C)=O
InChI
1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)
InChI 密鑰
HWLFIUUAYLEFCT-UHFFFAOYSA-N
生化／生理作用
Lenvatinib (E7080)是一种针对多种受体酪氨酸激酶的口服活性抑制剂，包括VEGFR (Flt-1/KDR/Flt-4 IC50 = 22/4.0/5.2 nM)、PDGFR1/2 (IC50 = 39/51 nM)、FGFR1和KIT (IC50分别= 46和100 nM)，可抑制体外血管生成（VEGF/ scf诱导HUVEC管形成IC50 = 5.1/5.2 nM）。口服Lenvatinib可导致产生scf的人小细胞肺癌H146细胞的小鼠体内肿瘤生长停滞(30 mg/kg b.i.p.o)甚至退化(100 mg/kg b.i.p.o)。
口服活性受体酪氨酸激酶抑制剂(Flt-1/KDR/Flt-4)， PDGFR1/2, FGFR1和KIT具有抗血管生成的体外和体内疗效。
訊號詞
Warning
危險聲明
危險分類
Repr. 2 - STOT RE 2
標靶器官
Gastro-intestinal system,Kidney,Bone,Reproductive organs,Adrenal gland
儲存類別代碼
11 - Combustible Solids
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Haijing Deng et al.
Liver cancer, 9(3), 338-357 (2020-07-11)
Combining anti-angiogenic therapy with immune checkpoint blockade with anti-programmed cell death-1 (PD-1) antibodies is a promising treatment for hepatocellular carcinoma (HCC). Tyrosine kinase inhibitors are well-known anti-angiogenic agents and offer potential for combination with anti-PD-1 antibodies. This study investigated the
Mariko Aoyama et al.
Oncology reports, 44(4), 1709-1716 (2020-09-19)
Anaplastic thyroid carcinoma (ATC) is a rare type of thyroid carcinoma with a poor prognosis. Thus, suitable preclinical tumor models are required for the development of new ATC therapies. In the present study, orthotopic tumor xenograft models were established using
Reina Sasaki et al.
International journal of molecular sciences, 21(9) (2020-05-14)
Multiple kinase inhibitors are available for patients with advanced hepatocellular carcinoma (HCC). It is largely unknown whether regorafenib or lenvatinib modulates innate immunity including Toll-like receptor (TLR)-signaling pathways in HCC. We performed real-time RT-PCR to investigate 84 TLR-associated gene expression
Wan-Ning Li et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(41), 25859-25868 (2020-10-03)
Endometriosis is a highly prevalent gynecological disease with severe negative impacts on life quality and financial burden. Unfortunately, there is no cure for this disease, which highlights the need for further investigation about the pathophysiology of this disease to provide
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门